TANZEUM is a GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. TANZEUM is not recommended as first-line therapy for patients inadequately controlled on diet and exercise because of the uncertain relevance of the rodent C-cell tumor findings to humans; prescribe only to patients for whom the potential benefits are considered to outweigh the potential risk. Has not been studied in patients with a history of pancreatitis; consider other antidiabetic therapies in patients with a history of pancreatitis. Not indicated in the treatment of patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis; is not a substitute for insulin in these patients. Has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis; is not recommended in patients with pre-existing severe gastrointestinal disease. Has not been studied in combination with prandial insulin.
TANZEUM is the only once-weekly GLP-1 receptor agonist studied head-to-head in a Phase III trial versus prandial insulin in patients taking basal insulin"scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1 Learn More
The safety and efficacy of TANZEUM have been evaluated in a clinical trial program comprising 8 Phase III studies with 2365 patients who received TANZEUM"scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"2 Learn More
TANZEUM offers 12 months of savings for your eligible patients. Subject to eligibility. Restrictions apply. Learn More
GLP-1 = glucagon-like peptide-1.